Q

QuidelOrtho

Develops, produces, and markets diagnostic tests

Overview

QuidelOrtho provides in vitro diagnostics (IVD) products, including diagnostic tests and equipment that use immunoassay and molecular testing to detect medical conditions. Its products are used in point-of-care settings, clinical laboratories, and transfusion medicine, serving individual healthcare providers to large institutions. The company develops and manufactures these tests and devices, which run on specialized platforms or point-of-care instruments to analyze patient samples and deliver quick, accurate results. What sets QuidelOrtho apart is its long history and the combination of Quidel’s and Ortho’s expertise into a broad portfolio, with a global reach and long-term contracts with healthcare providers. The company’s goal is to improve diagnostic accuracy and efficiency to support better patient outcomes and broad access to essential diagnostic solutions.

Significant Headcount Growth

Work here?Claim your company

About QuidelOrtho

Simplify's Rating
Why QuidelOrtho is rated
C+
Rated B on Competitive Edge
Rated C on Growth Potential
Rated C on Differentiation

Industries

Industrial & ManufacturingBiotechnologyHealthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, CA

Founded

1937

Get referred to QuidelOrtho

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Q3 2026 operating cash flow turned positive; free cash flow reached breakeven.
  • Management expects over $80 million annual savings from restructuring starting in 2027.
  • VITROS 450 launched November 2, 2026 across China, APAC, EMEA, and Latin America.

What critics are saying

  • China pricing changes cut Q3 2026 revenue 45%; management expects 2027 pressure.
  • Net debt reached $2.8 billion and 4.5x leverage, forcing covenant relief through 2028.
  • Levi & Korsinsky launched a November 9, 2026 securities probe after the 14% post-earnings drop.

What makes QuidelOrtho unique

  • QuidelOrtho spans labs, point-of-care, molecular, and transfusion testing across one portfolio.
  • Its VITROS 450 targets low-volume labs with waterless, compact chemistry automation.
  • The November 2026 two-business structure sharpens accountability versus conglomerate diagnostics rivals.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$3.4B

Above

Industry Average

Funded Over

1 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Employee Stock Purchase Plan
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Employee Assistance Program

Stock Price

Growth & Insights and Company News

6 month growth

7%

1 year growth

7%

2 year growth

7%
PR Newswire
Nov 9th, 2026
Levi & Korsinsky probes QuidelOrtho after 14% share drop and $100M restructuring

Law firm Levi & Korsinsky is investigating QuidelOrtho (NASDAQ: QDEL) for potential securities law violations after the company's shares fell about 14%. The drop followed QuidelOrtho's third-quarter 2026 results, which included a narrowed full-year revenue outlook and a restructuring programme. Company disclosures describe the programme as about $100 million and running through 2027. The investigation examines whether QuidelOrtho made misleading statements about its near-term outlook, including liquidity and revenue expectations. In an August 7, 2026 quarterly report, the company said its cash and credit facility would fund its needs for at least 12 months. That report showed negative operating cash flow of $143.6 million and $426.5 million of remaining revolver availability.

Yahoo Finance
Nov 6th, 2026
QuidelOrtho shares fall 55% as revenue shrinks and $1.5B point-of-care sale targets debt

QuidelOrtho shares have fallen 55.4% since the start of the year, including dividends, even as the diagnostics maker narrowed its loss. The stock now trades at $12.84, down from $28.56 on January 1, 2026. Third-quarter revenue fell from $699.9 million to $618.9 million, and the company still reported a loss. Falling COVID demand and high debt weighed on sentiment. QuidelOrtho is exploring a $1.5 billion sale of its point of care unit, with proceeds framed as a way to cut debt. Analyst views split widely. The bullish case put fair value at $40.33, while the bearish case set it at $26.

Yahoo Finance
Nov 3rd, 2026
QuidelOrtho posts $53.8M Q3 loss on $618.9M revenue

QuidelOrtho Corporation, a San Diego-based medical diagnostics company, reported a third-quarter loss of $53.8 million on Tuesday. That works out to a loss of 78 cents per share. Adjusted for one-time gains and costs, earnings were 31 cents per share. Revenue for the period was $618.9 million. For the full year, the company expects earnings of 65 cents to 70 cents per share and revenue of $2.52 billion to $2.54 billion.

Yahoo Finance
Nov 3rd, 2026
QuidelOrtho Q3 revenue falls 12% to $619M; restructuring to save over $80M annually

QuidelOrtho reported third-quarter 2026 revenue of $619 million, down 12% from a year earlier. The San Diego diagnostics company cited lower sales in China, after changes to In Vitro Diagnostics pricing, and a softer respiratory season. Net loss was $54 million, and adjusted EBITDA was $148 million. Point of Care revenue fell 27% to $120 million, while Labs revenue fell 6% to $353 million. Outside China, Labs revenue grew 3%. The company launched a cost transformation and restructuring program that it expects to save over $80 million a year in 2027. It will record about $30 million to $35 million in one-time charges in the fourth quarter. It will also reorganise around two businesses, Core Diagnostics and Point of Care Diagnostics.

Pathology in Practice
Nov 2nd, 2026
QuidelOrtho launches VITROS 450 chemistry system.

QuidelOrtho launches VITROS 450 chemistry system. * November 02, 2026 QuidelOrtho has launched the VITROS 450 chemistry system, a next-generation analyser designed to empower low-volume and community-based laboratories with high-quality, reliable results. Compact yet powerful, the VITROS 450 System enables laboratories to do more with less - supporting patient care in rural clinics, urban satellite laboratories and network facilities. It offers intuitive design and proven technology, making it ideal for laboratories seeking quality without compromise. This launch marks an important milestone in advancing diagnostic access and quality across diverse healthcare environments. The VITROS 450 System is now available in key markets around the world, including China, Asia-Pacific, Europe, Middle East and Africa and Latin America. Waterless operation eliminates the need for plumbing or drains and simplifies maintenance. The system keeps testing simple, consistent and dependable regardless of who is at the bench, supporting teams with diverse experience levels. The compact footprint suits laboratories with limited space. Waterless operation and the overall system design helps reduce operational waste and energy use.

Recently Posted Jobs

Sign up to get curated job recommendations

QuidelOrtho is Hiring for 17 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs